Comparative Pharmacology
Head-to-head clinical analysis: PAPA DEINE 4 versus ROXICET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAPA DEINE 4 versus ROXICET.
PAPA-DEINE #4 vs ROXICET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
None Documented
None Documented
2-4 hours. In hepatic or renal impairment, half-life may increase to 4-6 hours, requiring dose adjustment.
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Renal: ~90% (70% as glucuronide conjugates, 10% as morphine, 10% as normorphine). Biliary/fecal: ~10%.
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination